Jaysynth Orgochem Schedules Board Meeting on May 27, 2026 to Approve Q4 and Full-Year FY26 Financial Results

Jaysynth Orgochem Limited has informed BSE Limited of its upcoming 02/2026-27 Board Meeting, scheduled to be held on Wednesday, May 27, 2026. The meeting will be convened pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary agenda is to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026.

Board Meeting Details

The following table summarises the key details of the scheduled board meeting:

Parameter: Details Meeting Reference: 02/2026-27 Board Meeting Date: Wednesday, May 27, 2026 Time: 12:00 Noon Venue: 301, Sumer Kendra, P.B. Marg, Worli, Mumbai – 400 018 Agenda: Audited Standalone and Consolidated Financial Results for Q4 and FY ended March 31, 2026 Regulatory Framework: Regulation 29 read with Regulation 33, SEBI (LODR) Regulations, 2015

Trading Window Closure

In accordance with the Code of Practices and Procedures for Fair Disclosures and Conduct, and pursuant to the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, the company had earlier communicated the closure of the trading window. The key dates related to the trading window are outlined below:

Parameter: Details Trading Window Closed From: Wednesday, April 1, 2026 Trading Window Closed Until: Friday, May 29, 2026 Trading Window Reopens: Saturday, May 30, 2026

The trading window closure applies to dealings in the equity shares of the company by designated persons and their immediate relatives, as mandated under applicable SEBI regulations. The window will remain closed for 48 hours after the declaration of the financial results, consistent with regulatory requirements.

Regulatory Communication

The intimation was filed on May 18, 2026, and addressed to the Corporate Relationship Department of BSE Limited. The notice was signed by Riddhi Kunal Saraiya, Company Secretary and Compliance Officer (Membership No. A50707), on behalf of Jaysynth Orgochem Limited.

Jaysynth Orgochem Limited has submitted a regulatory disclosure to BSE Limited confirming its non-applicability as a Large Corporate under Securities and Exchange Board of India (SEBI) regulations. The disclosure, dated April 16, 2026, addresses compliance requirements under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.

Company's Regulatory Status

The company has formally confirmed that it does not meet the applicability criteria for Large Corporate classification as specified in the SEBI circular. This determination is based on the company's financial position and borrowing levels as of the specified reporting date.

Financial Position Details

The disclosure reveals key financial information about the company's borrowing status:

Parameter Details Company Name Jaysynth Orgochem Limited CIN L24100MH1973PLC016908 Outstanding Borrowing (as on March 31, 2026) ₹0.00 Cr Credit Rating Status Not Applicable Stock Exchange for Fine Payment Not Applicable

The company reported zero outstanding borrowings as of March 31, 2026, which is a significant factor in determining its non-qualification as a Large Corporate under the SEBI framework.

Regulatory Compliance Framework

Under the SEBI circular, entities identified as Large Corporates are subject to specific borrowing requirements through debt securities. The regulations stipulate that beginning from FY2022, any shortfall in mandatory borrowing through debt securities would attract a fine of 0.20% of the shortfall amount, levied by stock exchanges at the end of the two-year block period.

Since Jaysynth Orgochem Limited does not qualify as a Large Corporate, these mandatory borrowing requirements and associated penalty provisions are not applicable to the company.

Official Authorization

The disclosure was officially signed by two key executives of the company:

Riddhi Kunal Saraiya - Company Secretary and Compliance Officer

Mangesh Narayan Patil - Chief Financial Officer

Both officials can be reached at contact number 022 4938 4200/4300 for any regulatory or compliance-related queries.

Implications for Stakeholders

This confirmation provides clarity to investors and stakeholders regarding the company's regulatory status and compliance obligations. The zero borrowing position indicates a debt-free status as of March 31, 2026, which may be viewed favorably by investors seeking companies with strong balance sheet positions.

The disclosure ensures transparency in regulatory compliance and helps maintain the company's good standing with stock exchange requirements and SEBI regulations.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.